Head-to-head evidence
Pegmolesatide (HS-20039) vs rESP
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
Pegmolesatide (HS-20039)
Marketed by Hansoh Pharmaceutical Group
NCT03902691 · Phase 3 · completed
This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.
Next expected readout: December 2026 · NCT07136792 (registry estimate)
rESP
Developed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pegmolesatide (HS-20039)'s landscape · rESP's landscape